background. Clostridium difficile infection (CDI) has been extensively described in healthcare settings; however, risk factors associated with community-acquired (CA) CDI remain uncertain. This study aimed to synthesize the current evidence for an association between commonly prescribed medications and comorbidities with CA-CDI. methods. A systematic search was conducted in 5 electronic databases for epidemiologic studies that examined the association between the presence of comorbidities and exposure to medications with the risk of CA-CDI. Pooled odds ratios were estimated using 3 meta-analytic methods. Subgroup analyses by location of studies and by life stages were conducted.
evidence remains inconclusive in the community setting. Therefore, the current meta-analysis was undertaken to pool the evidence from observational studies so that the magnitude and direction of the association between commonly prescribed medications and comorbidities with CA-CDI can be documented.
methods

Search Methodology
A systematic search was undertaken in 5 medical and life sciences databases (PubMed, Embase, Cochrane CENTRAL, Cumulative Index to Nursing and Allied Health Literature [CINAHL] , and Scopus) from their inception to March 1, 2014 (Appendix 1). A related citation search was also performed; by combining the systematic search with the first 20 studies from the related citation search of selected articles in PubMed, a comprehensive evaluation of the published evidence can be achieved. 15 
Eligibility Criteria
The inclusion of studies was restricted to human studies, fulltext articles written in English, studies reporting CA-CDI, and data presented in an extractable format. Conference presentations and abstracts, studies that exclusively compared CA-CDI with HA-CDI, and studies that presented data in a nonextractable format (ie, graphical representations) were excluded. Exclusions were also made for studies that investigated specific groups (ie, patients with human immunodeficiency virus or cirrhosis) because these were not considered representative of the general population.
Study Selection and Data Extraction
Two authors (L.F.-K. and J.C.S.) independently evaluated all the citations by titles and abstracts for studies that met the eligibility criteria. Full-text version articles of all potentially relevant studies were retrieved and independently assessed for eligibility. Data from the included studies were then independently extracted using a predefined tool (Appendix 2) and summarized in a spreadsheet by the same 2 authors. Extracted data were cross-checked by the 2 authors, and discrepancies during the selection of studies or data extraction were resolved through discussion and consensus following independent evaluation by another author (S.A.R.D.).
Quality Assessment
The quality of each study was assessed using a modified version of the Newcastle-Ottawa quality assessment scale for casecontrol studies. The modified scale assessed whether 7 safeguards against bias had been undertaken by the authors: (1) definition of cases and methods employed for C. difficile diagnosis, (2) selection of CA infection, (3) control definition and the method used to rule out C. difficile, (4) selection of controls from the community, (5) analysis adjusted for confounders, (6) method used for ascertainment of exposure, and (7) same method used to ascertain exposure for cases and controls. The quality criteria were combined into a univariate score as outlined in Table 1 . The quality score was rescaled between zero and 1 (called Qi); this was done by summing the points of each component (maximum sum = 17) and dividing it by the highest sum obtained by a study within the meta-analysis, ensuring that the best quality study always had a Qi of 1.
Statistical Analyses
The outcome measure was the odds ratio (OR) for the association of CA-CDI with exposure to risk factors, such as antimicrobial drugs, gastric acid suppressant drugs (proton-pump inhibitors [PPI] and histamine-2-receptor antagonists), nonsteroidal antiinflammatory drugs, aspirin, steroids, and the presence of comorbidities. The OR was pooled using 3 meta-analytic models. This was justified because some have expressed skepticism regarding the appropriateness of the conventional RE model 16 owing to its documented underestimation of the statistical error, which leads to overconfident results. 5, [17] [18] [19] The other 2 models that were used were the quality effects (QE) model [20] [21] and a novel method, the inverse variance heterogeneity (IVhet) model. 22 The QE model uses the Qi to redistribute the inverse variance weights in favor of the studies with higher methodologic quality and thus studies that provided higher quality of evidence contributed with a higher weighting towards the overall effect size. 21 This use of quality information via a univariate score does not imply that quality deficiencies can quantify bias. Rather, the quality score is used to rank studies by methodologic rigor and this rank is then linked with a synthetic bias variance that is added to the random error variance. 20 The other model used was the IVhet model that does not require input of quality information and so is less rigorous than the QE model. 22 Both of the latter models use a quasi-likelihood-based variance structure without distributional assumptions and thus have coverage probabilities for the confidence interval (CI) well above the nominal level. 22 The reported results are based on the IV het model; results using the QE and RE models have been presented for comparative purposes.
Statistically significant heterogeneity was defined as tausquared statistic (τ 2 ) > 0, Cochran's Q test P < .1, or I 2 index >0%. A sensitivity analysis was conducted to determine the degree to which the findings vary depending on the geographic location where the studies were conducted (America or Europe) and life stages of the participants (children aged <2 years, children and adults, adults, or adults aged >65 years).
The Doi plots were used to evaluate the presence of publication bias, which plots the lnOR against the absolute value of the z-score for each study. 23 Funnel plots were not reported because the graphical assessment of publication bias requires at least 10 studies and even then can be difficult to interpret. 24 The results of the analyses were considered statistically significant if the 95% CI did not include zero. Analyses were conducted using MetaXL, version 2.0 (EpiGear International). 
results
Yield of Search Strategy
The initial search identified 1,663 publications. An additional 124 publications were retrieved throughout the related citations search. After excluding duplicate citations, 1,481 publications remained. After screening the publications by title and abstract, 1,388 were excluded. A full-text review of 93 publications was conducted, and 12 met the eligibility criteria and were selected for the meta-analysis ( Figure 1 ). There was overlap in subjects between 2 sets of publications. Two publications (Dial et al 25 29 were excluded from the analyses.
Characteristics of the Included Studies
Twelve publications were included in the meta-analysis. Two publications reported results divided into groups. Kutty et al 30 presented the results of 2 populations (Veterans Affairs and Durham County residents), whereas Soes et al 28, 29 presented the results divided into 2 age groups (<2 years and ≥2 years). Among the included studies, 7 were case-control studies and 5 were nested case-control studies. The studies included covered more than 35 years of research and 56,776 patients in 6 different countries. The age of the participants ranged from 3 months to 101 years. Only one study 28, 29 used exclusively positive C. difficile culture in the case definition and another study 31 used a combination of C. difficile culture or toxin test results in the case definition. All studies evaluated exposure to medication for at least 6 weeks and presence of comorbidities for at least 12 weeks prior to the index date, respectively ( Table 2 ). The quality score of the studies ranged from 9 to 13 of 17 (Table 1) .
Quantitative Synthesis
When examining the association between drug exposures and CA-CDI using the IVhet model, exposure to antimicrobials (OR, 6.18; 95% CI, 3.80-10.04) and corticosteroids (1.81; 1.15-2.84) were significantly associated with CA-CDI. Gastric acid-suppressing drugs were not associated with increased odds of CA-CDI (both PPIs and histamine-2-receptor antagonists: OR,1.58; 95% CI, 0.90-2.75; just PPIs: 1.61, 0.90-2.88; just histamine-2-receptor antagonists:1.24, 0.76-2.01). Statistically significant associations were found between CA-CDI and the presence of inflammatory bowel disease (OR, 3.72; 95% CI, 1.52-9.12), renal failure (2.64, 1.23-5.68), leukemia or (Table 3 and Appendix 3) confirmed heterogeneity across studies, except for exposure to tetracyclines or aspirin and the presence of chronic obstructive pulmonary disease, diabetes, or diverticular disease.
Sensitivity Analysis
A sensitivity analysis was possible only for antimicrobial and PPI exposure because of the small number of studies in the other categories. When stratifying the studies by geographic location, the sensitivity analysis showed that antimicrobial exposure had a greater association with CA-CDI in the United States (OR, 9.16; 95% CI, 5. 
4).
Publication Bias
On visual inspection of the Doi plots, there was gross asymmetry for some exposures, suggesting publication bias in relation to cephalosporins, fluoroquinolones, macrolides, penicillin, presence of congestive heart failure, and presence of gastroesophageal reflux disease. The bias was toward selective publication that reported medication exposure and presence of comorbidities as risk factors for CA-CDI (Appendix 3).
discussion
Exposure to antimicrobials remained the strongest risk factor associated with CA-CDI. No statistical significance was observed in most analyses by antimicrobial class, likely because Despite the growing evidence in the past decade with respect to increased risk of HA-CDI after exposure to PPIs 6,7,9-11 or histamine-2-receptor antagonists, 8, 25 no significant association was observed in the community setting. The observed difference between the risk of CA-CDI and HA-CDI with gastric-acid suppressive medication can be explained by the overuse of these medications in healthcare facilities. 33 Exposure to corticosteroids was associated with CA-CDI. In contrast to antimicrobials that disrupt the normal gut microbiome, facilitating the proliferation of C. difficile, 34 and in contrast to gastricacid suppressive medication that may allow survival of vegetative forms of C. difficile, 35 a plausible biological mechanism for the observed association could be the negative impact of corticosteroids on the gastrointestinal mucosal integrity. 36 Previous studies found that gastrointestinal comorbidities such as inflammatory bowel disease 12 and cirrhosis 14 were associated with a worse prognosis in patients with CDI. Similarly, congestive heart disease, chronic pulmonary disease, renal failure, and malignant neoplasms were also associated with higher mortality rates among inpatients with CDI. 13 Among the comorbidities examined in this meta-analysis, inflammatory bowel disease was the strongest risk factor for CA-CDI, followed by renal failure and hematologic cancers. In patients with the described comorbidities, early identification and prompt treatment of CA-CDI may reduce mortality rates. The associations found between CA-CDI and comorbidities may be confounded by medication exposure, given that polypharmacy is common among patients with multiple comorbidities. Furthermore, the heterogeneous definition of CA-CDI across the studies (ie, not hospitalized the year prior to the index date versus not hospitalized 6 weeks prior to the index date) may also be a source of misclassification between CA-and HA-CDI, considering that patients with multiple comorbidities are more likely to be admitted to hospitals.
The sensitivity analyses suggested that risk of CA-CDI with exposure to antimicrobials and PPI differed between Europe and America. The observed difference might be due to the dissimilar prescription of antimicrobials 37 and/or the presence of different strains of C. difficile in Europe and America. 38 Similarly, the risk of CA-CDI with exposure to antimicrobials and PPI varied among the life stages. These findings were consistent with Sandora et al, 39 who reported a negative correlation between age and CA-CDI among pediatric populations, and with Lessa et al, 40 who reported a higher incidence of CDI among patients at both extremes of life (1-4 years of age and older than 65 years). In the past 2 decades, a 12-fold increased incidence of CA-CDI among the pediatric population 41 and numerous outbreaks in long-term care facilities 42 have been reported, indicating that infants, toddlers, and older adults should be considered at high risk of CA-CDI. Although a comprehensive systematic search for studies was performed, publication bias could have resulted in additional positive associations being published, such as those between CA-CDI and exposure to cephalosporins, fluoroquinolones, macrolides, and penicillins and the presence of congestive heart disease and gastroesophageal reflux disease. The actual risks attributable to these risk factors could be less than what we have reported. Nevertheless, heterogeneity across studies could also result in effect size asymmetry, and this represents an alternative explanation to selective publication of positive results.
Recent meta-analyses have investigated the risk of CDI associated with exposure to antimicrobials 3, 4, 6 and gastric acid suppressant drugs [6] [7] [8] [9] using the widely adopted RE model. 16 However, the coverage probability of the RE CI can be substantially below the nominal level of 95% and thus does not adequately reflect the statistical error, especially when there are few included studies. 5, 22, 43 By underestimating the statistical error, the RE model produces tight CIs that potentially cause overconfident results prone to type 1 error. Moreover, the assumption of normally distributed random effects is not easily verified. 43 The use of a moment-based common variance 16 within this model is in the redistribution of the weights from larger to smaller studies. 18 The QE and IVhet models have both been created to do away with the problems that affect the RE model and both have coverage of the CI at or above the nominal level. 22 As an example, with the clindamycin pooled estimates, the IVhet model distributed the weight (83.5%) toward the biggest study (Lowe et al 32 ; n = 13,692). The QE model took into account the extra information regarding the quality of the studies and penalized the biggest study by reducing the assigned weight (from 83.5% to 69.0%) because it had the lowest quality score; whereas the RE model redistributed the weights by equalizing weights (by transferring from big to small studies) and thus, it gave a weight percentage to the biggest study (Lowe et al 32 ; n = 13,692; weight 25.85%) that was similar to that of the smallest study (Vesteinsdottir et al 44 ; n = 333; weight 23.98%). Moreover, the RE model produced a tighter CI (with a statistically significant result), but its coverage may have been under the nominal level and thus may not have captured the true value of the effect (Appendix 3.3).
Several limitations of the present meta-analysis were noted. Kuntz et al 2 and Marwick et al 31 reported a positive relationship between duration of exposure to antimicrobials and CA-CDI. However, the small number of studies precluded a subgroup analysis by duration of exposure to antimicrobials. All studies included in this meta-analysis were conducted in Northern Hemisphere countries. A recent study has described a different seasonal pattern of CDI in Australia that remains largely unexplained. 45 The epidemiologic patterns of C. difficile transmission and infection may differ between hemispheres and thus generalizability of the findings to Southern Hemisphere countries is limited.
In conclusion, while antimicrobial use remains the dominant risk factor for CA-CDI, corticosteroid use should also meta-analysis of risk factors for ca-cdi 139 be considered an important risk factor. Given these are commonly prescribed medications in the community, the attributable risk of CDI due to exposure may be high and thus further research is warranted. In addition, patients with inflammatory bowel disease, renal failure, and hematologic cancer are at higher risk of CA-CDI, making them appropriate populations for interventional studies of screening for C. difficile. Potential conflicts of interest. All authors report no conflicts of interest relevant to this article.
